Pharmacological targeting of VDAC has a significant therapeutic potential in several diseases including cancer, neurodegeneration, cardiovascular, and obesity where altering mitochondrial physiology through VDAC may be beneficial. The gene discussed is VDAC1; the disease is obesity disorder.